drugset / Trial / NCT00480467

Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-315 in Healthy Japanese Males

NCT00480467 ↗

Phase 1 Completed 32 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
RandomizedSingle-groupDouble-blindTreatment

Summary

To assess the safety and tolerability of ascending single oral doses of SAM-315, an investigational drug, in healthy Japanese male subjects.To obtain preliminary pharmacokinetic (PK) and pharmacodynamic (PD) profiles of SAM-315 in healthy Japanese male subjects.

Timeline

Start
2006-09
Primary completion
—
Completion
2007-08

Drugs

EvaluationDrugModalityDoseRoute
Subject SAM-315 Unknown — Oral

Indications